98%
921
2 minutes
20
Carbapenem-resistant Gram-negative bacilli (CR-GNB) are a critical public health threat, and carbapenem use contributes to their spread. Antimicrobial stewardship programs (ASPs) have proven successful in reducing antimicrobial use. However, evidence on the impact of carbapenem resistance remains unclear. We evaluated the impact of a multifaceted ASP on carbapenem use and incidence of CR-GNB in a high-endemic hospital. An interrupted time-series analysis was conducted one year before and two years after starting the ASP to assess carbapenem consumption, CR-GNB incidence, death rates of sentinel events, and other variables potentially related to CR-GNB incidence. An intense reduction in carbapenem consumption occurred after starting the intervention and was sustained two years later (relative effect -83.51%; 95% CI -87.23 to -79.79). The incidence density of CR-GNB decreased by -0.915 cases per 1000 occupied bed days (95% CI -1.743 to -0.087). This effect was especially marked in CR- and CR-, reversing the pre-intervention upward trend and leading to a relative reduction of -91.15% (95% CI -105.53 to -76.76) and -89.93% (95% CI -107.03 to -72.83), respectively, two years after starting the program. Death rates did not change. This ASP contributed to decreasing CR-GNB incidence through a sustained reduction in antibiotic use without increasing mortality rates.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190633 | PMC |
http://dx.doi.org/10.3390/antibiotics10050586 | DOI Listing |
Zhonghua Yi Xue Za Zhi
August 2025
The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an 710061, China.
In recent years, infections caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) and other multidrug-resistant (MDR) pathogens have posed significant challenges in solid organ transplantation (SOT). SOT recipients who develop CR-GNB infections face risks such as graft loss, respiratory failure, leading to a mortality rate exceeding 40%. This review examines the current resistance landscape and the characteristics of MDR infections in SOT recipients, discussing the epidemiological features of CR-GNB infections in SOT patients, the resistance profiles and mechanisms of common CR-GNB (e.
View Article and Find Full Text PDFSupport Care Cancer
July 2025
Infectious Diseases Department, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.
Purpose: To describe the outcome of cancer patients who present bloodstream infections (BSIs) by Gram-negative bacteria (GNB) and to analyze the impact of carbapenem resistance.
Methods: A retrospective study from 2021 to 2023 at a tertiary care oncologic center in Mexico. The study describes demographic, clinical, and microbiological characteristics in oncological patients with GNB-BSI.
Infect Drug Resist
June 2025
Department of Clinical Laboratory, The First Hospital of Jiaxing, The Affiliated Hospital of Jiaxing University, Jiaxing, 314000, People's Republic of China.
Objective: To elucidate the distribution characteristics and drug resistance of carbapenem-resistant gram-negative bacteria (CR-GNB) within a general hospital setting from 2019 to 2024.
Methods: The distribution characteristics of CR-GNB and antimicrobial resistance patterns among inpatients from 2019 to 2024 were investigated. The detection rate, departmental distribution, annual trends, and drug susceptibility profiles of key carbapenem-resistant bacterial species were compared.
Antimicrob Resist Infect Control
May 2025
Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: In the past decades, the prevalence of carbapenem-resistant Gram-negative bacteria (CR-GNB) has increased on a global scale. Here, we outline the infection prevention and control (IPC) interventions for addressing the prevalence of carbapenem-resistant Acinetobacter baumannii (CRAB) and carbapenem-resistant Klebsiella pneumoniae (CRKP).
Methods: A quasi-experimental study design was performed during the seven periods of 6-months from September 2018 to September 2021 in a large ICU in an Iranian hospital.
Front Pharmacol
March 2025
Department of Pharmacy, The Second Xiangya Hospital, Institute of Clinical Pharmacy, Central South University, Changsha, China.
Objectives: Infection with Carbapenem-resistant Gram-negative bacteria (CR-GNB) poses further challenges in treating stroke-associated pneumonia (SAP) patients. This multicenter retrospective study aimed to evaluate the efficacy of polymyxin B (PMB) in CR-GNB-infected SAP patients and to identify factors that may influence its effectiveness.
Methods: From 1 September 2019, and 30 December 2022, a total of 196 CR-GNB-infected SAP patients from five hospitals in China were included in the study based on specific criteria.